选择性 5-羟色胺再摄取抑制剂（SSRIs）在伴有和不伴有广场恐怖症的惊恐障碍治疗中的价值。

The value of selective serotonin re-uptake inhibitors (SSRIs) in the treatment of panic disorder with and without agoraphobia.

机构信息

Psychiatric Hospital and Outpatient Clinic of the University of Munich, Ludwig Maximilian Universitdt (LMU), Munich, Germany.

出版信息

Int J Psychiatry Clin Pract. 1997;1(1):59-67. doi: 10.3109/13651509709069206.

DOI:10.3109/13651509709069206

PMID:24926982

Abstract

Many promising medical and psychotherapeutic treatment approaches have been developed for panic disorder with or without agoraphobia in recent years. Previously, good results have been seen with the TCAs (imipramine, clomipramine) and alprazolam. This review represents a comprehensive survey of all existing studies of the efficacy of the selective serotonin re-uptake inhibitors (SSRIs) paroxetine and fluvoxamine. There is conclusive evidence that the effectiveness of these drugs-paroxetine in particular-can be regarded as proven. Moreover, there are indications that a quicker response and better tolerability can be achieved than with TCA. A phased therapy model demonstrates how SSRIs can amplify and therefore improve the treatment of panic disorder. Reference is also made to differential indications with regard to the severity and the duration of the disorder. (Int J Psych Clin Pract 1997; 1: 59-67).

摘要

近年来，针对伴有或不伴有广场恐惧症的惊恐障碍，已经开发出许多有前途的医学和心理治疗方法。以前，三环抗抑郁药（丙咪嗪、氯米帕明）和阿普唑仑的疗效较好。这篇综述全面调查了选择性 5-羟色胺再摄取抑制剂（SSRIs）帕罗西汀和氟伏沙明治疗惊恐障碍的所有现有研究。有确凿的证据表明，这些药物（尤其是帕罗西汀）的有效性可以被认为是已证实的。此外，有迹象表明，与三环抗抑郁药相比，它们可以更快地起效，且患者的耐受性更好。阶段性治疗模式表明 SSRIs 如何增强从而改善惊恐障碍的治疗。还提到了根据疾病的严重程度和持续时间的差异指征。（Int J Psych Clin Pract 1997; 1: 59-67）。